Navigation Links
EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical
Date:7/6/2010

OXFORD, England and LANGHORNE, Pennsylvania, July 6, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan. Under the terms of the companies' agreement, Ohara will be responsible for any late-stage development required by the Japanese authorities, and will pay EUSA an upfront fee and royalties on future sales.

Erwinase is an L-asparaginase derived from Erwinia chrysanthemi, which is used to treat acute lymphoblastic leukemia in combination with other anti-neoplastic agents. It is currently approved for use in Canada and in a number of countries in Europe, the Middle East and Asia, and is undergoing registration procedures in several other territories.

"This agreement represents an important strategic milestone for EUSA as it extends the reach of our partnership network to the Japanese market for the first time," said Bryan Morton, EUSA Pharma's President and Chief Executive Officer. "In the past four years EUSA has made great progress building a broad portfolio of marketed products and a specialty commercial infrastructure in Europe and North America. At the same time we have put in place a wider distribution network to bring our products to patients in over 80 countries around the world. Our n
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 29, 2007 /PRNewswire/ -- D-Pharm announced,today that the ... compound DP-b99 in the treatment of acute ischemic,stroke ... The data will be presented by the study's ... May 31st at,14.30 in the Carron Room, at ...
... Evidence is,accumulating that depression is a risk factor ... Women's Health Watch. A,recent study found that people ... selective serotonin reuptake inhibitors,(SSRIs) had double the rate ... research points to depression itself as a source,of ...
Cached Medicine Technology:DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 2DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 3Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch 2
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
(Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... Discomfort contributes to the falls that plague older adults, ... Falls are a leading cause of death among older ... to those accidents. , "Pain contributes to functional decline ... that could predispose to fall," the study authors wrote. ...
... , ... (HTDS; http://www.htdsmedical.com/ ) and its operating subsidiary Slavica Bio ... shareholders. HTDS management continues due diligence with the EU stem ... announcement on or about Oct 29, 2009 which the company ...
... 24 The Guardian Life Insurance Company of America ... a leading provider of employee benefits for small and ... to follow its current insurance coverage guidelines for mammography ... Cancer Society and American Medical Association (AMA) recommendations for ...
... Researchers at Ben-Gurion University of the Negev are ... including melanomas that aren,t visible to the naked eye. ... Imaging) revealed new textures of lesions that have never ... were diagnosed with various skin lesions and were awaiting ...
... Reston, Va.SNM will hold its Conjoint Mid-Winter Meetings ... Center in Albuquerque, N.M. This year, SNM joins ... Annual Meeting and Educational Symposium of the American ... Molecular Imaging Summit and the Clinical Trials Network ...
... sevenfold, study finds, , TUESDAY, Nov. 24 (HealthDay ... in the community are increasingly showing up among ... become infected, new research says. , From 1999 ... the incidence of outpatients with methicillin-resistant Staphylococcus ...
Cached Medicine News:Health News:Chronic Pain Trips Up Seniors 2Health News:Chronic Pain Trips Up Seniors 3Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3Health News:Guardian to Continue Following Its Current Coverage Guidelines for Mammography Screenings 2Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3
Advanced operating microscope with zoom and variable focus up to 500 mm....
... system microscope provides surgeons with brighter, crisper, ... are ideal for many minimally invasive spine ... at every point of contact. The first ... surgical microscope allows intuitive user guidance similar ...
The Horizontal-Vertical (H/V) lumbar valve system is the only differential pressure valve for lumbo-peritoneal shunting, which addresses orthostatic overdrainage....
Micro Dissecting Curette, 5 1/2", Round....
Medicine Products: